PBAC's latest decision on Risankizumab: Recommended with restriction (2023). Considered for Severe chronic plaque psoriasis in adults who have failed to achieve adequate response with at least two prior therapies.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
6
first 2019
PBS spend
$97M
18,110 scripts · 2024
Eligible population
Adults with severe chronic plaque psoriasis who have failed or ceased to respond to at least two prior therapies (methotrexate, cyclosporin, acitretin, apremilast, deucravacitinib, or phototherapy) and have PASI score >15 for whole body disease or specified severity for localised disease.
Therapy area
Dermatology
Line of therapy
Later-line
Evidence base
RCT
Primary endpoint
ORR
Comparator
risankizumab 75 mg PFS (two pack); alternatively, least costly biologic among ixekizumab, guselkumab, and bimekizumab
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design
PBS expenditure
The Australian government paid $97M in PBS benefits for Risankizumab in 2024 across 18,110 scripts, at $5,376 per script.
Submission history
Jul 2019: Recommended with restriction · Authority Required
Nov 2021: Recommended · Restricted
Mar 2022: Recommended with restriction · Authority Required
Mar 2022: Recommended with restriction · Restricted
Jul 2022: Recommended with restriction · Authority Required
Nov 2023: Recommended with restriction · Authority Required